|
Mar 13
|
Mesoblast Successfully Completes Placement and Accelerated Entitlement Offer
|
|
Mar 10
|
United States Food & Drug Administration (FDA) Supports Accelerated Approval Pathway for Rexlemestrocel-L in End-Stage Heart Failure Patients with a Left Ventricular Assist Device (LVAD)
|
|
Feb 29
|
Mesoblast First Half 2024 Earnings: EPS Beats Expectations, Revenues Lag
|
|
Feb 28
|
Mesoblast Reports Financial Results and Operational Update for Half-Year Ended December 31, 2023
|
|
Feb 26
|
Mesoblast Financial Results and Corporate Update Webcast
|
|
Jan 9
|
Mesoblast (ASX:MSB) investors are sitting on a loss of 88% if they invested three years ago
|
|
Jan 5
|
Mesoblast Limited (MESO) Loses -5.45% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
|
|
Dec 21
|
5 Stocks to Ride the Santa Claus Rally
|
|
Nov 26
|
Mesoblast Files for Orphan Drug and Pediatric Rare Disease Designations for Rexlemestrocel-L as Treatment for Severe Congenital Heart Disease
|
|
Nov 15
|
Avid Bioservices (CDMO) Moves 9.0% Higher: Will This Strength Last?
|
|
Sep 30
|
10 Best ASX Stocks To Invest In
|